Showing 2191-2200 of 2657 results for "".
- Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMDhttps://modernod.com/news/adverum-biotechnologies-granted-priority-medicines-prime-designation-by-european-medicines-agency-for-advm-022-in-wet-amd/2480943/Adverum Biotechnologies announced that the European Medicines Agency (EMA) has granted ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related macular degeneration (AMD). Adverum’s lead gene therapy candidate, ADVM-022, is a one-time, intr
- Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabeticshttps://modernod.com/news/ocuphire-granted-new-us-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics/2480941/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330, for diabetic eye disease. In addition, a new publication supporting the nov
- Kuria Therapeutics and Scohia Pharma Announce Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activatorhttps://modernod.com/news/kuria-therapeutics-and-scohia-pharma-announce-licensing-agreement-for-ophthalmic-and-dermal-rights-to-sco-116-a-novel-nrf2-activator/2480933/Kuria Therapeutics and Japanese biotech company Scohia Pharma announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of Scohia's internally discov
- EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of Uveitis Treatment Yutiq in Chinahttps://modernod.com/news/eyepoint-pharmaceuticals-and-ocumension-therapeutics-announce-approval-of-nda-by-chinas-nmpa-for-uveitis-treatment-yutiq/2480925/EyePoint Pharmaceuticals and OcuMension Therapeutics announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chr
- Ace Vision Group Appoints Elizabeth Yeu, MD, as Chief Strategic Advisorhttps://modernod.com/news/ace-vision-group-appoints-elizabeth-yeu-md-as-chief-strategic-advisor/2480922/Ace Vision Group announced that Elizabeth Yeu, MD, partner at Virginia Eye Consultants, has been appointed to the role of chief strategic advisor. In her new position, Dr. Yeu will manage AVG's clinical advancement strategy. As a surgeon, researcher, and educator, Dr.
- Samsara Vision and Lansheng Medical “MyVision” Announce Collaboration to Commercialize the SING IMT in Chinahttps://modernod.com/news/samsara-vision-and-lansheng-medical-myvision-announce-collaboration-to-commercialize-the-sing-imt-in-china/2480907/Samsara Vision announced it will collaborate with Lansheng Medical “MyVision,” a China-based company focused on ophthalmology, to develop a clinical and commercial organization to support Samsara Vision’s SING IMT (Smaller-Incision New-Generation Implantable Miniature
- Aurion Biotech Appoints Michael Goldstein, MD, as President and Chief Medical Officerhttps://modernod.com/news/aurion-biotech-appoints-dr-michael-goldstein-as-president-and-chief-medical-officer/2480904/Aurion Biotech announced it has appointed Michael Goldstein, MD, as president and chief medical officer. Dr. Goldstein will lead the company’s clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cel
- The Vision Council Announces that Version 3.13 of the Data Communication Standard is Now Availablehttps://modernod.com/news/the-vision-council-announces-that-version-313-of-the-data-communication-standard-is-now-available/2480893/The Vision Council announced the publication of Version 3.13 of the Standard for Data Communications. The standard, which is used by manufacturers of optical lab equipment and producers of software used in optical labs, was developed by The Vision Council’s Lens Proce
- Novartis Receives FDA Approval of Beovu for the Treatment of Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-approval-of-beovu-for-the-treatment-of-diabetic-macular-edema/2480891/Novartis announced that the FDA has approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). Today’s approval represents the second FDA-approved indication for Beovu, which was first approved for the treatment of wet age-related macular degeneration in
- New Study Highlights Patient Willingness to Adhere to Pre-Op Prephttps://modernod.com/news/new-study-highlights-patient-willingness-to-adhere-to-pre-op-prep/2480874/Bruder Healthcare announced new research that supports cataract surgeons and comanaging optometrists and ophthalmologists as they help patients prepare for surgery. This noninterventional, cross-sectional investigation of 278 US adults age 65 and older sought to identify cataract s